This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Amgen Inc.. Active years: 2012.
Company Filing History:
Years Active: 2012
Title: Unveiling the Innovations of Eileen J Johnson
Introduction:
Eileen J Johnson, a pioneering inventor based in Newbury Park, CA, has made significant contributions to the field of pharmaceuticals with her groundbreaking patent on CGRP peptide antagonists and conjugates. Her innovative work at Amgen Inc. has propelled the development of novel treatments for migraines, showcasing her dedication to advancing healthcare solutions.
Latest Patents:
Eileen J Johnson's pivotal patent revolves around a composition of matter involving a CGRP peptide antagonist. This patent not only introduces a pharmaceutical composition comprising the said matter and a pharmaceutically acceptable carrier but also presents a method for its production. Moreover, the patent discloses methods for treating, preventing, or mitigating migraines, underscoring Eileen's commitment to enhancing patient care.
Career Highlights:
Throughout her illustrious career, Eileen J Johnson has exemplified excellence in the pharmaceutical industry, revolutionizing treatment modalities for neurological disorders like migraines. Her innovative approach and scientific acumen have led to the development of cutting-edge therapies, underscoring her status as a visionary inventor in the field.
Collaborations:
Eileen J Johnson has collaborated closely with esteemed coworkers such as Colin Victor Gegg, Jr., and Leslie Phillip Miranda at Amgen Inc. Their combined expertise and collaborative efforts have undoubtedly played a pivotal role in driving forward innovative research and development initiatives in the pharmaceutical sector.
Conclusion:
In conclusion, Eileen J Johnson's inventive prowess and unwavering dedication to advancing healthcare technologies have solidified her reputation as a trailblazer in the field of pharmaceutical innovation. Her groundbreaking work on CGRP peptide antagonists and conjugates stands as a testament to her commitment to improving patient outcomes and shaping the future of healthcare.
